FDA warned APG Seven that its supplement labels claim to treat cancer, diabetes and other diseases, making them unapproved new drugs.
What happened
FDA bought samples and labeling of the dietary supplements BioMoringa and BioDiabetin through the phone number on the company's website, and reviewed the website www.alpagi.net in April 2024 and the Facebook page "Productos naturales Alpagi." No inspection was done. FDA found that labels, website and a May 3, 2023 Facebook post claim the products cure, treat or prevent diseases such as cancer, diabetes, osteoporosis, lupus and fungal infections.
What FDA found
The products are drugs because their labels and other labeling say they cure, treat or prevent disease.
Section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The products are new drugs sold without FDA approval, and FDA has no scientific data showing they are safe and effective for these uses.
Sections 201(p), 301(d) and 505(a) of the Act [21 U.S.C. 321(p), 331(d), 355(a)]BioMoringa, BioDiabetin, Maca Plus, Ginkgo Biloba and BioCell are misbranded because they lack adequate directions for use, since their claimed uses need a licensed practitioner's supervision.
Section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5Shipping these misbranded drugs across state lines is illegal.
Section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks the company to write back within 15 working days describing the specific steps taken to fix the violations and prevent them from recurring, with supporting documents. If the fixes cannot be finished in that time, the company must explain the delay and say when they will be done.
Who should pay attention
- retailers and online sellers offering these supplement brands
- supplement brands that use similar disease-treatment claims on labels or social media
- consumers who buy products by phone from Spanish-language natural product sellers
This is a summary. Read the original letter on fda.gov.